Yuwa Oka1, Hidemoto Saiki1, Yasumasa Hashimoto1,2, Yuta Terada1,3, Takashi Nakamura1,4, Takashi Ayaki3, Satoshi Orimo5, Sadayuki Matsumoto1. 1. Department of Neurology Kitano Hospital, Tazuke Kofukai Medical Research Institute Osaka Japan. 2. Department of Molecular Therapy National Center of Neurology and Psychiatry, National Institute of Neuroscience Kodaira Japan. 3. Department of Neurology Kyoto University Graduate School of Medicine Kyoto Japan. 4. Department of Neurology Osaka Saiseikai Nakatsu Hospital Osaka Japan. 5. Department of Neurology Kanto Central Hospital of the Mutual Aid Association of Public-School Teachers Tokyo Japan.
Abstract
BACKGROUND: Mutations in the tau gene linked to chromosome 17 cause frontotemporal dementia and parkinsonism (FTDP-17). OBJECTIVE: This study presents 3 Japanese familial cases diagnosed with N279K tau gene mutation, including 1 autopsy-confirmed case. METHODS: We compared the clinical presentations, cognitive functions, and images between the 3 familial cases diagnosed with N279K mutation. RESULTS: All 3 patients presented symptoms in their early 40s. One patient showed severe cognitive dysfunction and died in his sixth year after onset. The remaining 2 cases presented with parkinsonism-dominant clinical features. Among the 2 cases, 1 presented the characteristic symptoms of progressive supranuclear palsy. The pathological features of the dementia-dominant case showed frontal and temporal lobe-dominant neuronal loss and gliosis. Tau-positive neuronal and glial inclusions were found throughout. Further, tufted astrocytes and globose tangles were present whereas there were no Pick bodies and astrocytic plaques, compatible with pathology-confirmed frontotemporal lobar degeneration (FTLD) -tau subtypes. CONCLUSIONS: Patients with FTDP-17 can be classified into the following 2 major groups: dementia and parkinsonism-plus predominant phenotypes. Among our 3 cases, 1 showed dementia predominance whereas the other 2 showed parkinsonism predominance. Mutations in the microtubule-associated protein tau (MAPT) present with several pathological features. Clinically, our case presented a behavioral variant frontotemporal dementia (bvFTD). However, morphologically, the observed glial and neuronal pathology met the criteria for progressive supranuclear palsy (PSP). This study highlights the clinical heterogeneity within and between families with same MAPT mutation. Few pathologically confirmed PSP cases have been reported with mutations in MAPT.
BACKGROUND: Mutations in the tau gene linked to chromosome 17 cause frontotemporal dementia and parkinsonism (FTDP-17). OBJECTIVE: This study presents 3 Japanese familial cases diagnosed with N279K tau gene mutation, including 1 autopsy-confirmed case. METHODS: We compared the clinical presentations, cognitive functions, and images between the 3 familial cases diagnosed with N279K mutation. RESULTS: All 3 patients presented symptoms in their early 40s. One patient showed severe cognitive dysfunction and died in his sixth year after onset. The remaining 2 cases presented with parkinsonism-dominant clinical features. Among the 2 cases, 1 presented the characteristic symptoms of progressive supranuclear palsy. The pathological features of the dementia-dominant case showed frontal and temporal lobe-dominant neuronal loss and gliosis. Tau-positive neuronal and glial inclusions were found throughout. Further, tufted astrocytes and globose tangles were present whereas there were no Pick bodies and astrocytic plaques, compatible with pathology-confirmed frontotemporal lobar degeneration (FTLD) -tau subtypes. CONCLUSIONS: Patients with FTDP-17 can be classified into the following 2 major groups: dementia and parkinsonism-plus predominant phenotypes. Among our 3 cases, 1 showed dementia predominance whereas the other 2 showed parkinsonism predominance. Mutations in the microtubule-associated protein tau (MAPT) present with several pathological features. Clinically, our case presented a behavioral variant frontotemporal dementia (bvFTD). However, morphologically, the observed glial and neuronal pathology met the criteria for progressive supranuclear palsy (PSP). This study highlights the clinical heterogeneity within and between families with same MAPT mutation. Few pathologically confirmed PSP cases have been reported with mutations in MAPT.
Authors: Glenda M Halliday; Yun Ju Christine Song; Helen Creasey; John G Morris; William S Brooks; Jillian J Kril Journal: Brain Date: 2006-03 Impact factor: 13.501
Authors: P M Stanford; G M Halliday; W S Brooks; J B Kwok; C E Storey; H Creasey; J G Morris; M J Fulham; P R Schofield Journal: Brain Date: 2000-05 Impact factor: 13.501
Authors: Y Tsuboi; M Baker; M L Hutton; R J Uitti; O Rascol; M-B Delisle; X Soulages; J R Murrell; B Ghetti; M Yasuda; O Komure; S Kuno; K Arima; N Sunohara; T Kobayashi; Y Mizuno; Z K Wszolek Journal: Neurology Date: 2002-12-10 Impact factor: 9.910
Authors: Zoe Arvanitakis; Robert J Witte; Dennis W Dickson; Yoshio Tsuboi; Ryan J Uitti; Jerzy Slowinski; Michael L Hutton; Siong-Chi Lin; Bradley F Boeve; William P Cheshire; Robert A Pooley; Julie M Liss; John N Caviness; Audrey J Strongosky; Zbigniew K Wszolek Journal: Parkinsonism Relat Disord Date: 2006-12-29 Impact factor: 4.891
Authors: L Skoglund; M Viitanen; H Kalimo; L Lannfelt; M E Jönhagen; M Ingelsson; A Glaser; R Herva Journal: Eur J Neurol Date: 2007-12-18 Impact factor: 6.089
Authors: Z K Wszolek; R F Pfeiffer; M H Bhatt; R L Schelper; M Cordes; B J Snow; R L Rodnitzky; E C Wolters; F Arwert; D B Calne Journal: Ann Neurol Date: 1992-09 Impact factor: 10.422
Authors: Shelley L Forrest; Jillian J Kril; Claire H Stevens; John B Kwok; Marianne Hallupp; Woojin S Kim; Yue Huang; Ciara V McGinley; Hellen Werka; Matthew C Kiernan; Jürgen Götz; Maria Grazia Spillantini; John R Hodges; Lars M Ittner; Glenda M Halliday Journal: Brain Date: 2018-02-01 Impact factor: 13.501